LILLY HUMALOG SHORT-ACTING INSULIN ANALOG RECOMMENDED FOR Rx-ONLY STATUS BY ADVISORY COMMITTEE DUE TO LACK OF PHARMACOKINETIC, SUBPOPULATION DATA
Executive Summary
Lilly's short-acting insulin analog Humalog should be available as a prescription-only alternative to human insulin, FDA's Endocrinologic & Metabolic Drugs Advisory Committee unanimously recommended Feb. 29.